Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues
- PMID: 26456776
- PMCID: PMC8031554
- DOI: 10.1111/jch.12718
Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues
Comment on
-
Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.J Clin Hypertens (Greenwich). 2016 Feb;18(2):121-8. doi: 10.1111/jch.12628. Epub 2015 Jul 30. J Clin Hypertens (Greenwich). 2016. PMID: 26224543 Free PMC article. Clinical Trial.
References
-
- Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305. - PubMed
-
- Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–2047. - PubMed
-
- 2013 USRDS annual data repot–Atlas ESRD. http://www.usrds.org/atlas.aspx. Accessed July 12, 2014.
-
- Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768–2774. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
